New mesothelioma drug turns cancer's own defenses against it

Scientists have developed an innovative experimental drug that fights mesothelioma, an aggressive asbestos-related cancer, by disabling PRX3—an antioxidant defense mechanism that tumors rely on to survive. In early clinical trials, the drug controlled disease progression in 67% of patients with encouraging survival outcomes. Mesothelioma has historically had limited treatment options, making this discovery particularly significant for patients with this devastating disease. The novel approach of exploiting cancer cells' own survival mechanisms could potentially be adapted to treat other cancer types, offering hope for broader therapeutic applications in oncology.